Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.82 |
| ▸ | CTSK | P43235 | 8/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 9/20 | 0.51 |
| ▸ | CTSL | P07711 | 6/20 | 0.51 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627375 | 1.00 | SYK (0.82) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL3271846 | 1.00 | SYK (0.82) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL14497009 | 0.95 | SYK (0.74) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL30489620 | 0.95 | SYK (0.74) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL28668267 | 0.95 | SYK (0.74) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL6310853 | 0.90 | SYK (0.82) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL6310847 | 0.90 | SYK (0.82) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL2627398 | 0.90 | SYK (1.00) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL6310843 | 0.90 | SYK (0.82) | SYKCTSKATMCTRB1CTSS | |
| SCHEMBL20674340 | 0.89 | SYK (0.80) | SYKCTSKATMCTRB1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1305454-A | Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | SYK 715/4885CTSK 2213/4885ATM 387/4885 |
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | SYK 1719/4885CTSK 3314/4885ATM 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.